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Introduction 
Pemphigus in an autoimmune blistering disease 
often associated with specific medications. 
Discontinuation of the offending medication is 
considered the treatment of choice.  Management of 
medication associated pemphigus can be difficult 
when the associated medication is vital to a patient’s 
survival.  We report a patient in whom the onset of 
pemphigus foliaceus was associated with imatinib 
mesylate therapy in a patient with resected 
gastrointestinal stromal tumor (GIST).  Imatinib was 
continued because of the survival benefit to the 
patient. Treatment with rituximab resulted in near 
resolution of his blistering rash; however, the disease 
returned after imatinib dose was increased a year 
later, suggesting a dose-response relationship. 
 
Case Synopsis 
An 80-year-old man diagnosed with an 11cm, c-kit-
positive gastrointestinal stromal tumor (GIST) with a  
Abstract 
Pemphigus is an autoimmune bullous disease with a 
number of described associations, including 
medications, which have been grouped into three 
structural categories — thiol drugs, phenol drugs, 
and drugs with neither functional group [1]. 
Discontinuation of the offending medication is 
considered a mainstay of therapy. We report a 
patient in whom the onset of pemphigus foliaceus 
was associated with initiation of imatinib mesylate 
adjuvant therapy in a patient with resected 
gastrointestinal stromal tumor (GIST). Imatinib was 
continued because of the survival benefit to the 
patient with a resected, high risk GIST. Treatment 
with rituximab resulted in near resolution of his 
blistering rash and follow up enzyme-linked 
immunosorbent assay (ELISA) demonstrated 
reference range immunoreactivity for both 
desmoglein 1 and desmoglein 3. After dose increase 
of imatinib therapy owing to tumor growth, the 
patient subsequently again developed a similar 
eruption. Re-biopsy and ELISA were consistent with 
recurrence of pemphigus. In conclusion, although 
the patient’s pemphigus was cleared with a single 
cycle of rituximab infusions while continuing 
imatinib therapy, the disease returned after imatinib 
dose was increased a year later, suggesting a dose-
response relationship. 
Figure 1. Initial presentation with erythematous, edematous and 
eroded papules and plaques scattered on the trunk and reaching 
confluence on the upper arms. With topical therapy and 
phototherapy, this eruption resolved. 
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high mitotic rate in the small bowel was 
subsequently treated with resection and adjuvant 
imatinib mesylate at a dose of 400mg daily. A few 
weeks after treatment initiation, he developed mild 
periorbital and lower extremity swelling with 
pruritus which subsided over the ensuing months. 
He then developed a whole body, pruritic eruption 
of pink, edematous plaques, small vesicles and tense 
bullae, and erosions 11 months after initiating 
imatinib therapy (Figure 1). Punch biopsy 
demonstrated superficial perivascular dermatitis 
with lymphocytes, histiocytes, and rare eosinophils 
consistent with a drug eruption (Figure 2). Direct 
immunofluorescence examination at this time was 
negative. The patient was treated with an oral 
prednisone taper over two weeks and a topical 
regimen of tacrolimus ointment to face, 
triamcinolone ointment to the body, and clobetasol 
ointment to worst areas, which resulted in 
improvement but incomplete clearance. He 
subsequently initiated narrow band ultraviolet B 
therapy three times weekly and underwent 27 
treatments with complete clearance of his rash. 
Phototherapy was decreased to once weekly, 
resulting in recrudescence of the eruption six weeks 
after tapering narrow band ultraviolet B therapy 
(Figure 3). 
At this time (approximately 18 months after initiation 
of imatinib therapy), a second biopsy demonstrated  
intraepidermal vesicular and spongiotic dermatitis 
with eosinophils, whereas direct immunofluo-
rescence was positive for intercellular IgG and C3 
fluorescence within the epidermis (Figure 4). 
Enzyme-linked immunosorbent assay (ELISA) 
demonstrated elevated reactivity to desmoglein 1 
(55.95, reference<14) and reference-range reactivity 
to desmoglein 3 (3.14, reference<9) consistent with 
Figure 2. Punch biopsy of the skin at initial presentation 
demonstrating superficial perivascular inflammatory infiltrate 
with eosinophils. H&E, 100×. 
 
Figure 3. A) Tapering of phototherapy resulted in recurrence of 
the rash with more prominent erythematous, edematous plaques, 
tense vesicles and bullae, and erosions on the chest. B) 
Erythematous edematous plaques with tense bullae and erosions 
on the forearm. 
A
B
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pemphigus foliaceus. Treatment with two doses of 
rituximab at 1000mg administered intravenously 
spaced two weeks apart resulted in marked 
improvement two months after therapy and near 
resolution of his blistering rash five months after 
therapy (Figure 5). Follow up ELISA two months after 
rituximab infusion demonstrated reference range 
immunoreactivity for both desmoglein 1 and 
desmoglein 3. Imatinib was continued throughout 
rituximab therapy to achieve three years of total 
treatment (stopped in June 2016).  
Unfortunately, the patient was found to have 
recurrence of his GIST approximately one year after 
imatinib discontinuation. He was restarted on 
imatinib therapy at the same dose of 400mg daily in 
July 2017, with the plan to keep patient on therapy 
long term per medical oncology. The patient noticed 
periorbital edema soon after restarting therapy and 
mild recurrence of rash, specifically a few isolated 
erosions and edematous papules on scalp and back, 
adequately managed with topical corticosteroids 6 
months after reinitiating therapy. Owing to 
progression of his cancer on 400mg daily of imatinib, 
the dosage was increased to 800mg daily in 
September 2018. A few weeks after this dose 
increase, the patient noticed worsening and was 
seen in dermatology clinic. At that time, he was 
found to have numerous scattered annular urticaria-
like plaques on the back and upper arms (Figure 6A). 
Punch biopsy of one of the annular lesions showed 
focal intraepidermal vesiculation with acantholysis 
(Figure 6B) and once again, ELISA demonstrated 
elevated reactivity to desmoglein 1 (27.25, 
reference<14) and reference-range reactivity to 
desmoglein three (0.47 reference<9) consistent with 
recurrence pemphigus foliaceus. Of note, the 
histopathology findings in this case were not specific 
to pemphigus foliaceous but are compatible with 
the disease when taken together with the direct 
immunofluorescence and ELISA findings.  
The patient has history of prostate cancer surgically 
resected 9 years prior to his presentation and 
Figure 4. A) Punch biopsy of the skin at relapse with clinical bullae 
demonstrating spongiosis, intraepidermal vesiculation, and 
eosinophils. H&E, 200×. B) Corresponding direct 
immunofluorescence of punch biopsy of skin at relapse showing 
positive intercellular C3 reactivity on examination, 400×. 
Figure 5. Clinical remission was achieved five months after one 
cycle of two rituximab infusions. 
A 
B 
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superficial urothelial cell bladder cancer treated with 
intravesical Bacillus Calmette-Guerin (BCG) therapy 
with recurrence and additional BCG therapy at the 
time of this report. His chronic medications included 
aspirin and levothyroxine. 
 
Case Discussion 
Imatinib mesylate was initially described as a 
clinically effective inhibitor of the oncogenic BCR-
ABL fusion kinase in chronic myelogenous leukemia 
and Philadelphia chromosome-positive acute 
lymphoblastic leukemia [2-4]. At the same time, it 
was shown to have an anti-tumor effect in metastatic 
GIST related to the cross inhibition of the tyrosine 
kinase c-kit [5]. Imatinib mesylate used in the 
adjuvant setting for resected GIST has demonstrated 
improved relapse-free survival and longer term 
treatment yields with better five-year survival [5, 6]. 
In general, imatinib therapy is well tolerated, though 
edema and rashes are frequently seen in a dose-
dependent fashion [3, 4, 7]. One prospective study 
characterized the majority of rashes as 
exanthematous or maculopapular eruptions, and 
less commonly severe exfoliative dermatitis, pustular 
eruption, and psoriasiform plaques [7]. Other 
manifestations reported include lichenoid rash, 
acute generalized exanthematous pustulosis, and 
Stevens-Johnson syndrome [8-11].  
Our patient exhibited the common cutaneous 
manifestation of periorbital and lower extremity 
edema. The temporal relationship between the 
onset of pemphigus foliaceus and the initiation of 
imatinib is circumstantially suggestive of a causal 
relationship. Although imatinib mesylate does not 
contain a thiol group like other better characterized 
causes of drug-induced pemphigus, it is a 
methanesulfonate salt that does coordinate the thiol 
group in a critical methionine residue in the 
nucleotide binding pocket of the Abelson kinase [2]. 
The pathogenesis of thiol drug-mediated 
pemphigus is not known, though postulated 
mechanisms include direct, drug-induced 
acantholysis, upregulation of acantholytic enzymes 
like plasminogen activator, and neoantigen 
formation [1, 12, 13].  
Aside from the temporal relationship between 
imatinib therapy initiation and the onset of 
pemphigus foliaceus, other characteristics of this 
presentation suggest a drug-related etiology rather 
than this representing a case of coincident idiopathic 
pemphigus foliaceus. The preceding eruption was 
typical of a drug-induced hypersensitivity eruption, 
and it responded very well to typical therapies for  
Figure 6. A) Scattered annular urticaria-like plaques on the back 
and upper arms. B) Punch biopsy of the skin of the left back after 
rash recurrence shows mild spongiosis, focal intraepidermal 
acantholysis, and a mixed inflammatory infiltrate with 
eosinophils. H&E, 200×. 
A
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hypersensitivity, including narrow band UVB 
phototherapy and topical corticosteroid therapies. 
The hypersensitivity eruption subsequently gave 
way to a bullous dermatosis with features not typical 
for idiopathic pemphigus foliaceus, including 
grouped, tense bullae in an annular configuration. In 
a recent case series of patients with drug-induced 
pemphigus, 16 of 17 were induced by thiol drugs, yet 
the phenotype of blistering disorder was variable 
despite the well-defined causes. The predominant 
type was that of classic pemphigus foliaceus, though 
there were a few cases of pemphigus herpetiformis 
type as well as unclassified types [13]. The case 
presented in this report certainly does not fit classic, 
idiopathic pemphigus foliaceus, though the 
phenotype of idiopathic pemphigus foliaceus with 
concomitant imatinib therapy is not known. 
Of note, a form of pemphigus — paraneoplastic 
pemphigus — is associated with certain 
malignancies such as non-Hodgkin lymphoma, 
chronic lymphocytic leukemia, and Castleman 
disease [14]. It is possible that the flaring of 
pemphigus in our patient could have been related to 
tumor recurrence rather than treatment. However, 
paraneoplastic pemphigus is characterized clinically 
by oral erosions often followed by polymorphic 
cutaneous disease and systemic manifestations [15]. 
The histopathology varies based on the type of skin 
lesions and direct immunofluorescence can show 
linear C3 and IgG deposits at the epidermal-dermal 
junction [16]. In addition, immunopathology can 
demonstrate antibodies to desmoglein 3, 
desmoplakin 1, BP230, desmoplakin 2, envoplakin, 
plectin, and epiplakin [17]. Paraneoplastic 
pemphigus has been associated with GIST [18]. 
However, our patient’s clinical and immuno-
pathological manifestations were compatible with 
pemphigus foliaceus rather than paraneoplastic 
pemphigus. 
It is important to note that the highly morbid skin 
disease in this patient did respond well to rituximab  
therapy. This allowed the continuation of adjuvant 
imatinib therapy for this patient whose tumor had a 
high risk of recurrence. Recent data demonstrates 
that three years of imatinib therapy in high risk GIST 
is superior to one year of therapy in both recurrence-
free survival at five years and overall survival [19]. 
To our knowledge, only one other case in the 
literature demonstrated imatinib-associated 
pemphigus foliaceous. However, in this case, 
imatinib was discontinued and treatment with 
prednisolone and azathioprine facilitated the 
resolution of the patient’s pemphigus. One month 
after reintroduction of imatinib, pemphigus recurred 
in this reported patient leading to indefinite 
discontinuation of imatinib [20].  
 
Conclusion 
Our case supports the observation that imatinib may 
induce pemphigus foliaceous, further confirmed by 
the development of this phenotype on two separate 
occasions, both after therapy initiation and dose 
increase. Most importantly, this case demonstrates 
that targeted therapy, specifically with rituximab, 
treats this imatinib toxicity and allows for 
continuation of anticancer therapy in high risk 
patients.  
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